The U.S. Rosacea Market: Size, Trends & Forecasts (2020-2024 Edition)
SCOPE OF THE REPORT
The report entitled “The U.S. Rosacea Market: Size, Trends & Forecasts (2020-2024 Edition)”, provides a detailed analysis of the U.S. rosacea market with market sizing and growth pattern. The analysis includes rosacea market in terms of value, volume and number of patients seeking treatment. The report also provides an overview of the U.S. dermatology drugs market in terms of value and market share by segments.
Furthermore, the report also assesses the key opportunities available in the market and summarizes the dynamic forces that are and will be accountable for growth of the industry. Growth of the U.S. rosacea market has also been forecasted for the period 2020-2024, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Foamix Pharmaceuticals Ltd., Galderma, Sol-Gel Technologies Ltd., and Allergan Plc are some of the major players whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies adopted by respective companies.
Company Coverage
Rosacea is a common disorder associated with skin and most prevalent among people with light skin tone, and mainly affects areas around the chin, cheeks, nose, and forehead. The main characteristic of this disease is solid-bumps and pus-filled pimples.
Rosaceais a common chronic condition of the skin with a high prevalence rate among the U.S. population. It naturally begins at any time after the age of 30 or previously. In some cases, rosacea may also occur on the neck, chest, scalp or ears. Rosacea symptoms and signs include facial flushing, fine red vascular lines, swollen, red eyelids and many more. Currently, more than 16 million populations in the U.S. are suffering from rosacea.
The U.S. rosacea market has grown over the past few years and is projected to grow at a high growth rate on the back of rising incidence of disease, and aging population. The growth in the market will be driven by unhealthy eating habits and environmental factors, rising disposable income, ageing population, escalating healthcare expenditure, high prevalence of rosacea, etc. Yet the market growth is restrained by factors such as lack of awareness and knowledge and stringent government regulations for the approval of new drugs.
The report entitled “The U.S. Rosacea Market: Size, Trends & Forecasts (2020-2024 Edition)”, provides a detailed analysis of the U.S. rosacea market with market sizing and growth pattern. The analysis includes rosacea market in terms of value, volume and number of patients seeking treatment. The report also provides an overview of the U.S. dermatology drugs market in terms of value and market share by segments.
Furthermore, the report also assesses the key opportunities available in the market and summarizes the dynamic forces that are and will be accountable for growth of the industry. Growth of the U.S. rosacea market has also been forecasted for the period 2020-2024, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Foamix Pharmaceuticals Ltd., Galderma, Sol-Gel Technologies Ltd., and Allergan Plc are some of the major players whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies adopted by respective companies.
Company Coverage
- Foamix Pharmaceuticals Ltd.
- Sol-Gel Technologies Ltd
- Galderma
- Allergan Plc
Rosacea is a common disorder associated with skin and most prevalent among people with light skin tone, and mainly affects areas around the chin, cheeks, nose, and forehead. The main characteristic of this disease is solid-bumps and pus-filled pimples.
Rosaceais a common chronic condition of the skin with a high prevalence rate among the U.S. population. It naturally begins at any time after the age of 30 or previously. In some cases, rosacea may also occur on the neck, chest, scalp or ears. Rosacea symptoms and signs include facial flushing, fine red vascular lines, swollen, red eyelids and many more. Currently, more than 16 million populations in the U.S. are suffering from rosacea.
The U.S. rosacea market has grown over the past few years and is projected to grow at a high growth rate on the back of rising incidence of disease, and aging population. The growth in the market will be driven by unhealthy eating habits and environmental factors, rising disposable income, ageing population, escalating healthcare expenditure, high prevalence of rosacea, etc. Yet the market growth is restrained by factors such as lack of awareness and knowledge and stringent government regulations for the approval of new drugs.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Overview of Rosacea
2.1.1 Symptoms of Rosacea
2.1.2 Causes of Rosacea
2.1.3 Types of Rosacea
2.1.4 Treatment of Rosacea
3. THE U.S. MARKET ANALYSIS
3.1 The U.S. Dermatology Drugs Market Analysis
3.1.1 The U.S. Dermatology Drugs Market by Value
3.1.2 The U.S. Dermatology Drugs Market by Segments (Rosacea and Other)
3.2 The U.S. Rosacea Market Analysis
3.2.1 The U.S. Rosacea Market by Value
3.2.2 The U.S. Rosacea Market by Volume
3.2.3 The U.S. Rosacea Market by Number of Patients Seeking Treatment
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Aging Population
4.1.2 Rising Disposable Personal Income
4.1.3 Escalating Healthcare Expenditure
4.1.4 Unhealthy Eating Habits and Environmental Factors
4.1.5 High Prevalence Rate of Rosacea
4.2 Challenges
4.2.1 Lack of Awareness
4.2.2 Stringent Government Regulations
4.3 Market Trends
4.3.1 Approval of New Drugs
5. COMPETITIVE LANDSCAPE
5.1 The U.S. Rosacea Market Players: A Financial Comparison
5.2 The U.S. Rosacea Drugs Competitive Landscape
5.3 The U.S. Rosacea Market Players Competitive Landscape
6. COMPANY PROFILES
6.1 Menlo Therapeutics Inc. (Foamix Pharmaceuticals Ltd.)
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.2 Sol-Gel Technologies Ltd.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy
6.3 Galderma
6.3.1 Business Overview
6.3.2 Business Strategy
6.4 Allergan Plc
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
2. INTRODUCTION
2.1 Overview of Rosacea
2.1.1 Symptoms of Rosacea
2.1.2 Causes of Rosacea
2.1.3 Types of Rosacea
2.1.4 Treatment of Rosacea
3. THE U.S. MARKET ANALYSIS
3.1 The U.S. Dermatology Drugs Market Analysis
3.1.1 The U.S. Dermatology Drugs Market by Value
3.1.2 The U.S. Dermatology Drugs Market by Segments (Rosacea and Other)
3.2 The U.S. Rosacea Market Analysis
3.2.1 The U.S. Rosacea Market by Value
3.2.2 The U.S. Rosacea Market by Volume
3.2.3 The U.S. Rosacea Market by Number of Patients Seeking Treatment
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Aging Population
4.1.2 Rising Disposable Personal Income
4.1.3 Escalating Healthcare Expenditure
4.1.4 Unhealthy Eating Habits and Environmental Factors
4.1.5 High Prevalence Rate of Rosacea
4.2 Challenges
4.2.1 Lack of Awareness
4.2.2 Stringent Government Regulations
4.3 Market Trends
4.3.1 Approval of New Drugs
5. COMPETITIVE LANDSCAPE
5.1 The U.S. Rosacea Market Players: A Financial Comparison
5.2 The U.S. Rosacea Drugs Competitive Landscape
5.3 The U.S. Rosacea Market Players Competitive Landscape
6. COMPANY PROFILES
6.1 Menlo Therapeutics Inc. (Foamix Pharmaceuticals Ltd.)
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.2 Sol-Gel Technologies Ltd.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy
6.3 Galderma
6.3.1 Business Overview
6.3.2 Business Strategy
6.4 Allergan Plc
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Types of Rosacea
Figure 2: The U.S. Dermatology Drugs Market by Value; 2015-2019 (US$ Billion)
Figure 3: The U.S. Dermatology Drugs Market by Value; 2020-2024 (US$ Billion)
Figure 4: The U.S. Dermatology Drugs Market by Segments; 2019 (Percentage, %)
Figure 5: The U.S. Rosacea Market by Value; 2016-2019 (US$ Billion)
Figure 6: The U.S. Rosacea Market by Value; 2020-2024 (US$ Billion)
Figure 7: The U.S. Rosacea Market by Volume; 2017-2019 (Million)
Figure 8: The U.S. Rosacea Market by Volume; 2020-2024 (Million)
Figure 9: The U.S. Rosacea Market by Number of Patients Seeking Treatment; 2018-2024 (Million)
Figure 10: Share of Old Age Population (65 years and Older) in the Total US Population; 2010-2050 (Percentage, %)
Figure 11: The US Disposable Personal Income; 2013-2018 (US$ Trillion)
Figure 12: The US Healthcare Expenditure; 2012-2018 (US$ Trillion)
Figure 13: Foamix Pharmaceuticals Ltd. Revenue; 2014-2018 (US$ Million)
Figure 14: Foamix Pharmaceuticals Ltd. Revenue by Source; 2018 (Percentage, %)
Figure 15: Foamix Pharmaceuticals Ltd. Revenue by Region; 2018 (Percentage, %)
Figure 16: Sol-Gel Technologies Ltd. Revenue; 2017-2019 (US$ Million)
Figure 17: Allergan Plc Net Revenue; 2015-2019 (US$ Billion)
Figure 18: Allergan Plc Net Revenue by Segments; 2019 (Percentage, %)
Table 1: The U.S. Rosacea Market Players: A Financial Comparison; 2018/2019
Table 2: The U.S. Rosacea Drugs Competitive Landscape
Table 3: The U.S. Rosacea Market Players Competitive Landscape
Table 4: Foamix Pharmaceuticals Product Candidate Pipeline
Table 5: Foamix Pharmaceuticals Ltd. Catalyst and Events Calendar
Table 6: Sol-Gel’s Clinical-Stage Pipeline
Table 7: Sol-Gel Catalyst Calendar
Figure 1: Types of Rosacea
Figure 2: The U.S. Dermatology Drugs Market by Value; 2015-2019 (US$ Billion)
Figure 3: The U.S. Dermatology Drugs Market by Value; 2020-2024 (US$ Billion)
Figure 4: The U.S. Dermatology Drugs Market by Segments; 2019 (Percentage, %)
Figure 5: The U.S. Rosacea Market by Value; 2016-2019 (US$ Billion)
Figure 6: The U.S. Rosacea Market by Value; 2020-2024 (US$ Billion)
Figure 7: The U.S. Rosacea Market by Volume; 2017-2019 (Million)
Figure 8: The U.S. Rosacea Market by Volume; 2020-2024 (Million)
Figure 9: The U.S. Rosacea Market by Number of Patients Seeking Treatment; 2018-2024 (Million)
Figure 10: Share of Old Age Population (65 years and Older) in the Total US Population; 2010-2050 (Percentage, %)
Figure 11: The US Disposable Personal Income; 2013-2018 (US$ Trillion)
Figure 12: The US Healthcare Expenditure; 2012-2018 (US$ Trillion)
Figure 13: Foamix Pharmaceuticals Ltd. Revenue; 2014-2018 (US$ Million)
Figure 14: Foamix Pharmaceuticals Ltd. Revenue by Source; 2018 (Percentage, %)
Figure 15: Foamix Pharmaceuticals Ltd. Revenue by Region; 2018 (Percentage, %)
Figure 16: Sol-Gel Technologies Ltd. Revenue; 2017-2019 (US$ Million)
Figure 17: Allergan Plc Net Revenue; 2015-2019 (US$ Billion)
Figure 18: Allergan Plc Net Revenue by Segments; 2019 (Percentage, %)
Table 1: The U.S. Rosacea Market Players: A Financial Comparison; 2018/2019
Table 2: The U.S. Rosacea Drugs Competitive Landscape
Table 3: The U.S. Rosacea Market Players Competitive Landscape
Table 4: Foamix Pharmaceuticals Product Candidate Pipeline
Table 5: Foamix Pharmaceuticals Ltd. Catalyst and Events Calendar
Table 6: Sol-Gel’s Clinical-Stage Pipeline
Table 7: Sol-Gel Catalyst Calendar
